Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine plus Rituximab in Low-grade Lymphomas

The study aimed to determine the cost-effectiveness of Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] in the firstline treatment of low-grade lymphoma compared to bendamustine + rituximab (BR). There were no differences in response rates or 5-years progression-free survival between the two groups. Patients who received (90)YIT had fewer oncology clinic visits, days of therapeutic use, and 40% less use of growth factors The aim of our study is to determine the cost-effectiveness of Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] in the first-line treatment of low-grade follicular lymphoma (LG-FL) and marginal zone B cell lymphoma (MZL). We included all patients who were treated with (90)Y-IT for previously untreated LG-FL and MZL (N = 51). A comparator arm with patients who received bendamustine + rituximab (BR) was used (N = 92). Inverse propensity weighting was utilized to balance the 2 study arms. There were no differences in overall response rate (100% vs. 98%, P = .18), complete response rate (94% vs. 95%, P = .91), or 5 years progression-free survival (76% vs. 75%, P = .63) between patients who received (90)Y-IT and BR, respectively. Patients who received (90)Y-IT required an average of 4.5 fewer oncology clinic visits ( P < .001), an average of 10 fewer days of therapeutic use ( P < .001), and 40% less use of growth factors ( P < .001). The direct therapeutic cost of (90)Y-IT treatment was 54% less than that of 6 cycles of BR. Background: Yttr ium-90 ibr itumomab tiuxetan [(90)Y-IT] is a CD20-targeted radio-immunotherapeutic agent. It has shown an excellent therapeutic activity with high tolerability against previously untreated follicular lymphoma (FL) and marginal zone B cell lymphoma (MZL). It is an attractive therapeutic option as the treatment schedule is short and convenient. The aim of our study is to determine the cost-effectiveness of (90)Y-IT in comparison to the standard-ofcare bendamustine + rituximab (BR) in the first-line treatment of low-grade FL (LG-FL) and MZL in the real world. Patients and Methods: We included all patients who were treated with standard-dose (90)Y-IT for previously untreated LG-FL and MZL at the Mayo Clinic Cancer Center (N = 51). A comparator arm with a historical cohort of previously untreated LG-FL and MZL patients who received BR was used (N = 92). Results: Inverse propensity weighting was utilized to balance the 2 study arms. There were no differences in terms of overall response rate (100% vs. 98%, P = .18), complete response rate (94% vs. 95%, P = .91), or 5 years progression-free survival (76% vs. 75%, P = .63) between patients who received (90)Y-IT and BR, respectively. Within the first year, patients who received (90)Y-IT required an